Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
about
Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat CancerThe use of (18)F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer.Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges.Ultrasonic Nanobubbles Carrying Anti-PSMA Nanobody: Construction and Application in Prostate Cancer-Targeted Imaging.Distinct antibody species: structural differences creating therapeutic opportunitiesPreclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Dual-Labeled Near-Infrared/(99m)Tc Imaging Probes Using PAMAM-Coated Silica Nanoparticles for the Imaging of HER2-Expressing Cancer Cells.Synthesis and pre-clinical evaluation of an (18)F-labeled single-chain antibody fragment for PET imaging of epithelial ovarian cancerAnti-tax interacting protein-1 (TIP-1) monoclonal antibody targets human cancers.Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.Nanobody-based cancer therapy of solid tumors.Improving the targeting of therapeutics with single-domain antibodies.Emerging site-specific bioconjugation strategies for radioimmunotracer development.Molecular imaging of tumors with nanobodies and antibodies: Timing and dosage are crucial factors for improved in vivo detection.Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: a versatile strategy for multiple molecular imaging modalities.Non-Invasive Imaging of Amyloid Deposits in a Mouse Model of AGel Using (99m)Tc-Modified Nanobodies and SPECT/CT.Al18F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging.Alternative reagents to antibodies in imaging applications.Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy.Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment.Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro and in vivo study.Aligning physics and physiology: Engineering antibodies for radionuclide delivery.Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment.Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma
P2860
Q26739702-034602A1-439B-4BCA-91CD-7A28390021B1Q27300759-DCD91E79-3B46-4105-8C66-CEA9ADCB19F1Q33935498-A37EF323-1771-46B2-BF69-C278BFD02B83Q35674555-CB184F12-88BF-4C3E-8D09-36D481B4A3ECQ36945545-3D6DB071-856C-4899-BD1B-F4F0F9A0691EQ36963554-14BFA473-1D8B-492B-9B78-87BA468C4ACDQ37085052-0B583CC9-99CD-4399-A443-3990BEA30718Q37134529-E1D6B940-71A3-4D19-B63D-1F1FC91BEB31Q37136748-BA5CE245-AB72-438D-BFB4-17024E317E40Q37536570-E6A6101D-6C5C-49F8-9F9A-CC81CEEA31C5Q38230884-AB9B1775-DEE5-485C-8216-A33AF736CC0FQ38322471-45F64722-B4A5-4348-BA9E-3E156E08CC89Q38675117-02CF7ACA-6390-463A-84B5-C6EFC67F25CEQ38818208-F90995B8-BD31-4873-9926-305CFF4627ABQ38880847-4EDAAA10-48B4-491B-BE0E-AAA7E16E4673Q39793253-DEAEA60F-0387-4AB3-A0C8-5A675435DEE7Q39808570-8E245366-AE5A-4251-837F-2C3DB7AC4DF6Q41455532-7D54966D-21D5-40F8-ADDE-38471B3870F3Q41579389-857AB990-2DEA-465D-8B4B-E7D20278D6C3Q47099672-020E5D95-386C-4C40-AE2F-BCCD8ADCB0CEQ47121798-B8270905-BE39-44C1-B89A-A6EF3A1D472BQ47134203-B7192A56-CCA7-4EA6-9562-5985F92FDC08Q49167649-ABAB3396-08A8-43E9-BDF4-3D86B36CEE84Q50068024-959E05BD-999B-4A18-B37D-840126221A1CQ50083411-EE1C6874-A240-456B-9FEC-D1E4D17C1886Q51740406-BAF6A85A-3DB7-4917-9B42-E2E447772D08Q52098663-272D75FD-3E3A-411D-B844-091AAA9F63D1Q52362264-5F266577-98E7-43B1-922E-F134BF2DB14CQ52657511-4F85C001-64A9-4791-A85E-E7B589A03AB2Q59133661-8D2DF0C0-02B0-48D6-BBB3-B417B9EC84F1
P2860
Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
@ast
Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
@en
type
label
Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
@ast
Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
@en
prefLabel
Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
@ast
Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
@en
P2093
P2860
P50
P356
P1433
P1476
Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
@en
P2093
Cécile Vincke
Hendrik De Raeve
Matthias D'Huyvetter
Nathalie Impens
Sarah Baatout
Tony Lahoutte
Vicky Caveliers
P2860
P304
P356
10.7150/THNO.8156
P577
2014-04-25T00:00:00Z